What is Royalty Pharma's JNJ‑4804 — total commitments?

Royalty Pharma (RPRX) reported JNJ‑4804 — total commitments of $500M in Q2 2026.

What does JNJ‑4804 — total commitments mean?

This metric represents the aggregate contractual obligation or total capital commitment allocated by the firm toward the acquisition or funding of royalty interests associated with the JNJ-4804 asset. It encompasses both the capital already deployed and the remaining obligations to be funded over the life of the agreement. This figure serves as a primary indicator of the firm's total financial exposure and investment scale in this specific biopharmaceutical product.

Royalty Pharma (RPRX) JNJ‑4804 — Total Commitments

Screener

Other product segments

Litifilimab

$250M—

Similar metrics at other companies

ABRStructured Business — Total Commitments

$166.07M-34.7%

OTFTotal commitments

$6.7M-13.0%

USBTotal outstanding commitments

$873.32B+8.8%

USBTotal outstanding commitments

$873.32B+8.8%

KNTKMinimum Volume Commitments — Total revenues

$2M+567%

LENMultifamily — Total equity commitments

$2.2B0.0%

Other financials

Income statement

See full

Revenue$674.1M+16.5%

Operating income$133.1M-36.5%

Net income$17.9M-44.4%

EPS (diluted)$0.04-42.9%

Balance sheet

See full

Cash & equivalents$812.0M+28.5%

Total debt$9.0B+11.7%

Total equity$9.8B+3.1%

Total assets$19.8B+8.2%

Cash flow

See full

Operating cash flow$728.5M+100%

Valuation

See full

Market cap$25.6B+63.7%

Enterprise value$33.75B+46.5%

P/E31.4×+16.1×

P/S10.1×+3.3×

Profitability

See full

Operating margin59.6%-20.2pp

Net margin32.1%-12.3pp

Returns & leverage

See full

Return on equity8.5%-2.2pp

Debt / equity0.9×+0.1×

Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept rprx:ResearchAndDevelopmentCommitments.

The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 9:02 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001802768-26-000015

Product Candidates	Counterparties	Total Commitments	Funding Timing	Unfunded Commitments
JNJ‑4804	Johnson & Johnson	$500,000	Eight fixed quarterly payments commencing in the second quarter of 2026	$437,500
TEV-’408(1)	Teva Pharmaceuticals	75,000	Variable quarterly payments commencing in second quarter of 2026	65,149
Litifilimab	Biogen	250,000	Six fixed quarterly payments commencing in first quarter of 2025	—
Total		$825,000		$502,649

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Royalty Pharma's JNJ‑4804 — total commitments?: Royalty Pharma (RPRX) reported JNJ‑4804 — total commitments of $500M in Q2 2026.
What does JNJ‑4804 — total commitments mean?: This metric represents the aggregate contractual obligation or total capital commitment allocated by the firm toward the acquisition or funding of royalty interests associated with the JNJ-4804 asset. It encompasses both the capital already deployed and the remaining obligations to be funded over the life of the agreement. This figure serves as a primary indicator of the firm's total financial exposure and investment scale in this specific biopharmaceutical product.